

1 Endoscopic assessment of presumed acquired pyloric narrowing in cats:

2 a retrospective study of 27 cases

3 Valérie Freiche*¹, Fiona Da Riz*¹, Ghita Benchekroun¹, Frédérique Degorce², Eve Laloy³,

4 Mathieu R. Faucher⁴, Alexander J. German⁵

5

6 ¹Université Paris Est, Ecole Nationale Vétérinaire d'Alfort, Unité de médecine interne, 94700,

7 Maisons Alfort, France

8 ²LAPVSO, 129 route de Blagnac, 31200 Toulouse, France

9 ³Université Paris Est, Ecole nationale vétérinaire d'Alfort, Unité d'Anatomo-pathologie, 94700,

10 Maisons Alfort, France

11 ⁴Clinique Vétérinaire Alliance, 8 boulevard Godard, 33300 Bordeaux, France

12 ⁵ Institute of Life Course and Medical Sciences, Faculty of Health and Life Sciences, University
13 of Liverpool, Neston, CH64 7TE, UK

14 *Valérie Freiche and Fiona Da Riz contributed equally to this work

15

16 Corresponding author: Fiona Da Riz DVM

17 Email address: fiona.dariz@vet-alfort.fr

18 Ecole Nationale Vétérinaire d'Alfort, département de médecine interne, 7 Avenue du Général de
19 Gaulle, 94700 Maisons-Alfort, France

20 Phone number: +33 6 79 92 18 23

21 Keywords: Pyloric stenosis, Pylorus, Inflammatory Bowel Disease, Gastritis, Endoscopy, feline

22

23 **Abstract**

24 Acquired pyloric narrowing is a rare and poorly-documented condition in cats, but the
25 endoscopic appearance of pyloric narrowing has never previously been reported. The objectives
26 of this study were to describe the clinical, endoscopic and histological features in cats with
27 gastrointestinal signs where the pylorus could not be passed during endoscopy, and to compare
28 these data with a control group.

29 Medical files of cats that underwent upper GI endoscopy by the same operator between 2006 and
30 2015 were reviewed. Cats for which the pylorus could not be passed were assigned to the case
31 group, whilst those with an easily-passable pylorus were assigned to the control group.

32 The case group comprised 27 cats and control group comprised 35 cats. Median age and weight
33 were not different between groups, but there were more Siamese cats in the case group (6/27)
34 compared with the control group (1/35; $P=0.04$). Chronic vomiting was the main clinical sign in
35 both groups, but the vomitus was more likely to contain food in case group (23/25) than in cats
36 in control group (17/30; $P<0.01$). Endoscopic findings confirmed gastric inflammation in both
37 groups, whilst histological findings revealed similar lymphoplasmacytic infiltration of the gastric
38 mucosa and the duodenum in most cases, neoplastic features being infrequent.

39 Acquired pyloric narrowing is probably an underdiagnosed condition in adult cats. A possible
40 association between pyloric narrowing and gastrointestinal inflammatory disease requires
41 further study but, for now, it is recommended that multiple gastric, pyloric, and duodenal
42 biopsies be acquired during the endoscopy.

43

44 **Introduction**

45 Pyloric stenosis is thought to be a rare condition in cats, with only a few congenital cases
46 described in kittens from either domestic shorthair cats or Siamese breeds (Pearson et al., 1974;
47 Syrcole et al., 2013; Twaddle, 1971, 1970). The reported clinical signs are compatible with gastric
48 retention syndrome (*ie*, delayed food vomiting after meals), with either radiography or
49 ultrasonography confirming either a full stomach several hours after eating or prolonged
50 retention of radiographic contrast after administration (Pearson et al., 1974; Syrcole et al., 2013).
51 Confirmation of the diagnosis is usually made at coeliotomy, and endoscopy has only been used
52 as a diagnostic tool in one case report (Syrcole et al., 2013; Twaddle, 1971, 1970). Delayed gastric
53 emptying results from several conditions such as gastric obstruction with foreign body or
54 neoplasia, gastric dysmotility, inflammatory or metabolic disease and pyloric stenosis (Washabau
55 and Day, 2013). Endoscopic assessment is required if metabolic disease and focal inflammation
56 (eg pancreatitis, peritonitis) have been excluded, in order to assess both gastric and duodenal
57 content and mucosa, allowing directed sampling for histopathologic analysis.

58

59 To the author's knowledge, acquired pyloric stenosis has never been described in cats. Moreover,
60 although the dimensions of the healthy feline pylorus have been studied ultrasonographically,
61 they have been described in only one study (Couturier et al., 2012). Ultrasonography can be useful
62 to detect muscular hypertrophy, or extraluminal obstruction, however it allows only external and
63 transmural assessment of the pylorus morphology, precluding evaluation of internal diameter
64 and gastric and pylori-duodenal mucosa. The pyloric sphincter should be readily intubated with
65 an 8.8 mm external diameter video endoscope by an experienced endoscopist (Tams and Rawling,
66 2011; Washabau and Day, 2013); therefore, the inability to intubate the pylorus despite several
67 attempts in normal conditions increases suspicion for acquired pyloric narrowing, providing
68 indirect evidence of pyloric stenosis. However, to the authors' knowledge this approach has

69 never been validated in the veterinary literature. Furthermore, endoscopy enables direct
70 examination of both gastric and pyloro-duodenal mucosa and luminal contents in order to
71 identify conditions which might be responsible for delayed gastric emptying, such as chronic
72 foreign bodies, pyloric polyps and pyloric neoplasia (Washabau and Day, 2013).

73 The aim of this retrospective study was to compare the clinical, imaging, endoscopic and
74 histologic characteristics of two groups of cats with gastrointestinal signs: a group with presumed
75 acquired pyloric narrowing defined by the inability to intubate the pylorus endoscopically, and
76 a control group characterised by the ability to pass an endoscope through the pylorus.

77

78 **Materials and Methods**

79 **Case selection and inclusion criteria**

80 This was a retrospective, cross-sectional, cohort study involving cats seen at two referral centres
81 (site 1: Centre Hospitalier Universitaire Vétérinaire d'Alfort, Ecole Nationale Vétérinaire d'Alfort,
82 France; site 2: Clinique Vétérinaire Alliance, Bordeaux, France). To identify eligible cases, the
83 patient medical record files of cats referred to site 1 and site 2 between 2006 and 2015 were
84 retrospectively reviewed. Eligibility criteria included: (1) cats referred to the gastroenterology
85 service at each institution and undergoing gastro-duodenoscopy between 2006 and 2015 in order
86 to investigate chronic gastrointestinal signs (*eg*, vomiting, diarrhoea, decreased appetite, weight
87 loss); (2) clinical records available including endoscopic and histologic reports; (3) endoscopy
88 performed by the same experienced endoscopist (VF); and (4) the medical records clearly
89 indicated whether the pylorus could be intubated during endoscopy. Control cases were chosen
90 equally over the whole study period to ensure that group differences did not exist as a result of
91 any improvement of the endoscopist's skill to intubate the pylorus. Cases were excluded if no
92 abdominal ultrasonography was performed or the record not available. All diagnostic
93 investigations were performed for the direct clinical benefit of the case, and owners gave
94 informed written consent.

95

96 **Case definition and study groups**

97 Cats were assigned to the presumed acquired pyloric narrowing group when the pylorus could
98 not be intubated successfully despite multiple attempts (*e.g.*, pyloric intubation was classified as
99 "severe" (3) or "moderate" (2) according to the World Small Animal Veterinary Association
100 [WSAVA] criteria during endoscopic evaluation). Cases were eligible for inclusion in the control
101 group when the pylorus was easily intubated during endoscopy (*e.g.*, pyloric intubation classified
102 as "normal" (0) or "mild" (1) according to the WSAVA criteria). Controls were ultimately

103 included according to the same inclusion criteria over the same period to ensure that the size of
104 both groups was approximately equal.

105

106 **Clinical signs, laboratory, and imaging data**

107 Information was recorded on signalment, dietary and medication history, clinical signs, and
108 physical examination findings (*e.g.*, body weight, temperature, thoracic auscultation findings and
109 abdominal palpation). Details of clinicopathological investigations were recorded when present;
110 a serum biochemistry profile was usually performed as part of the screening test and previous
111 the anaesthesia. Similarly, findings from abdominal ultrasonography were recorded, cases
112 without an ultrasonography report available were excluded.

113

114 **Endoscopy**

115 Prior to endoscopy, cats were fasted for at least 16h, and no premedication was used before
116 anaesthesia. General anaesthesia was induced with either propofol (Propovet Multidose, Zoetis)
117 at 4-6 mg/kg IV or thiopental (Nesdonal, Merial) at 20-22 mg/kg, and anaesthesia was
118 maintained using 2% isoflurane (Vetflurane, Virbac) with oxygen, after tracheal intubation.
119 Endoscopy was performed using a GIF 160 pediatric video gastroscope (Olympus), with an
120 external diameter of 8.8 mm. Cats were positioned in left lateral recumbency as previously
121 recommended (Tams and Rawling, 2011; Washabau and Day, 2013), with a mouth gag placed
122 immediately before intubation and left in place for as short a time as possible to minimise the risk
123 of amaurosis (Martin-Flores et al., 2014).

124

125 The duration of most procedures was about 20 minutes. The insertion tube was first advanced
126 into the oesophagus, through the mouth, and then advanced into the stomach through the cardia.
127 The stomach was partially insufflated (*i.e.*, the minimum amount of insufflation possible to

128 identify the position of the antrum and pylorus) to enable the endoscope to be advanced towards
129 the pylorus. A macroscopic evaluation of the antrum and the pylorus was then performed before
130 pyloric intubation was attempted, by advancing the tip of the endoscope to the pylorus and
131 applying gentle pressure. Four-to-six attempts were made (pressure applied to the pylorus
132 gradually increased) to pass the pyloro-duodenal junction. For cases where the pylorus was not
133 successfully passed, no further attempts were made in order to prevent any proximal duodenal
134 damage.

135

136 If the pylorus was passable, the proximal duodenum was macroscopically observed, gross
137 changes were scored and biopsy samples were collected. Thereafter, the endoscope was
138 withdrawn until the tip was back in the stomach, and other parts of the stomach were then
139 examined, their appearance scored, and biopsies collected. The diameter of the pyloric sphincter
140 was compared to the open biopsy forceps diameter (6mm) to estimate the internal pyloric
141 diameter in some cases, as previously described (Syrclé et al., 2013). At the end of the procedure,
142 a standardised endoscopic report was completed, which included grading of various
143 macroscopic findings (The WSAVA International Gastrointestinal Standardization Group, 2010).

144

145 **Histopathological analysis**

146 During endoscopy, multiple biopsies were collected from the region of the pylorus, antrum,
147 body, fundus and duodenum, with reusable biopsy forceps with oval fenestrated jaws (PE202300,
148 Optomed). In cases where the pylorus could not be intubated, duodenal biopsies were collected
149 blind by pyloric catheterisation as previously described (Willard et al., 2008). Biopsies were
150 placed in 10% neutral-buffered formalin (pH 7.4) in preparation for histopathological analysis;
151 those collected from cats seen at site 1 were submitted to the Biopôle (Maisons-Alfort, France)
152 whilst those collected from cats seen at site 2 were submitted to the LAPVSO (Laboratoire

153 d'Anatomie Pathologique Vétérinaire du Sud-Ouest, 31201 Toulouse, France). All samples from
154 the stomach were processed together, rather than assessing separate regions individually.
155 Samples were processed by routine methods for histological examination, and sections were
156 stained with haematoxylin and eosin before being interpreted by one EBVS® European Specialist
157 in Veterinary Pathology, according to the WSAVA recommendations (The WSAVA International
158 Gastrointestinal Standardization Group et al., 2010).

159

160 **Therapy and outcome**

161 When available, information about treatment (drug, time and dosage) clinical improvement and
162 follow-up were gathered. If the cat died, the date and cause of the death were recorded.

163

164 **Statistical analysis**

165 All data were entered into a spreadsheet, and statistical software (BiostatGV,
166 <https://marne.u707.jussieu.fr/biostatgv>) was used to assist with data analysis. Quantitative
167 variables (*e.g.*, age and weight) were described using median and range, and Mann-Whitney U-
168 tests were used to compare age and weight between groups. Qualitative variables were described
169 using percentages and compared between groups using either χ^2 tests, or Fisher's exact tests
170 when sample size was small (*e.g.*, when the expected values in any cell within a contingency table
171 was <5). Statistical significance was assumed when $P < 0.05$ for two-sided analyses.

172

173 **Results**

174 **Study population and signalment**

175 During the study period, 27 cats met the eligibility criteria, whilst 35 cats were assigned to the
176 control group. Signalment and clinical signs are summarised in Table 1. Most of the cats were
177 domestic shorthair (cases: 18/27, 66%; controls: 26/35, 74%), with a range of other breeds
178 represented (Table 1). Siamese cats were over-represented in the case group (6/27 vs. 1/35,
179 $P=0.04$). There were 12 males and 15 females, respectively, in the case group and 21 and 14 males
180 and females, respectively, in the control group, with no significant difference between groups
181 ($P=0.22$). All cats were neutered except for one cat in each group. The median age of cases and
182 controls was 8.0 years [range 2.0-14.5 years] and 9 years [range 0.7-18.0 years], respectively, with
183 no significant difference between groups ($P=0.47$). The median weight of cases and controls was
184 4.0 kg [range 2.3-6.0 kg] and 4.5 kg [range 2.4-7.1 kg], respectively, with no significant difference
185 between groups ($P=0.25$).

186

187 **Clinical signs, laboratory and imaging data**

188 Chronic vomiting was the most frequent clinical sign in both groups (cases: 18/22, 82%; controls:
189 28/34, 82%), with no significant difference between groups ($P=1$). Median duration of chronic
190 clinical signs was calculated (among precisely quantified data available) and was not different
191 between groups (cases: median 4 months [0.1-42 months]; controls: median 15.5 months [0.1-60
192 months]; $P=0.49$). Time of vomiting was recorded when available and was variable among cats;
193 vomiting could occur a few minutes to a few hours from meals. However, vomiting food was
194 more common in cases (23/25, 92%) compared with controls (17/30, 57%; $P<0.01$). Other clinical
195 signs included diarrhoea (cases: 6/27, 22%; controls: 10/35, 29%, $P=0.23$), decreased appetite
196 (cases: 4/27, 15%; controls: 11/35, 31%, $P=0.15$) and weight loss (cases: 10/27, 37%; controls:
197 16/35, 46%, $P = 0.61$). Serum biochemistry and haematology results are presented in Table 2 and

198 Table 3, respectively. None of the results for any cat were consistent with a systemic (*i.e.*, non-
199 gastrointestinal) origin for the clinical signs, and there were no significant differences between
200 groups.

201

202 **Ultrasonographic examination**

203 Abdominal ultrasound findings are presented In Table 4. Despite food withdrawal for 16 hours,
204 gastric contents were evident in 4 cats in each group ($P = 0.72$). Pyloric muscular layer thickening
205 was present in only 2 cats in case group and in 4 cats in control group ($P=0.69$), whilst muscular-
206 layer thickening was also evident in other regions in 8 cats in case group and 13 cats in control
207 group ($P=0.60$). Other ultrasonographic abnormalities included signs of chronic nephropathy
208 (cases: 4/27, 15%; controls: 7/35, 20%; $P=0.74$), hepatomegaly or change in liver echogenicity
209 (cases: 7/27, 26%; controls: 10/35, 29%; $P=1.0$), pancreas abnormality (cases: 1/27, 4%; controls:
210 5/35, 14%; $P=0.22$) or digestive (mesenteric, ileo-colic, gastric or hepatic) mild adenomegaly
211 (cases: 8/27, 30%; controls: 10/35, 29%; $P=1.00$).

212

213 **[please insert Figures 1 a and b]**

214

215 **Endoscopy**

216 Details of the gross endoscopic inspection of the stomach are provided in Table 5. Macroscopic
217 findings included oedema, hyperaemia, erosions, discolouration of the gastric mucosa, and were
218 present in both cases and controls, with no significant difference between groups (Table 5). Such
219 changes were present in any gastric region including fundus, corpus, antrum, cardia and lesser
220 curvature but not specifically at the pylorus level. Findings consistent with inflammation were
221 common and not statistically different between groups ($P>0.05$ for all). Other endoscopic lesions
222 identified included gastric foreign body (cases: 1/34, 3%; controls: 1/37, 3%; $P = 1.0$), abnormal

223 gastric content (cases: 1/27, 4%; controls: 1/35, 3%; $P=1.0$) and gastric mass or polyp (cases; 1/27,
224 4%; controls 4/35, 11%; $P=0.37$) localised in the body or antrum and not obstructing the pylorus.
225 An additional mucosal fold was reported in 5/27 (19%) cats in case group, beside the pylorus.
226 Besides the lesions described and the presence of a narrowed pyloric aperture (pyloric intubation
227 graded 2 to 3 in all cases), no other endoscopic findings were noted. Examples of endoscopic
228 appearance of narrowed pylorus are illustrated in Figure 2.
229 **[please insert figures 2(a), 2(b), 2(c)]**

230 **Histopathological analysis**

231 A summary of the histological findings in both cases and controls is given in Table 6. The most
232 common finding reported in the gastric mucosa was lymphoplasmacytic infiltration graded from
233 mild (score 1) to severe (score 3) according to WSAVA guidelines, but there was no difference in
234 the presence of such an infiltration between cases (18/27, 67%) and controls (21/35, 60%; $P=0.96$).
235 More specifically, there was no significant difference in the number of cats presenting mild,
236 moderate or severe lymphoplasmacytic infiltration between groups. Other histopathological
237 findings included eosinophilic infiltration of the gastric mucosa (cases: 2/27, 7%; controls: 1/35,
238 3%; $P=0.58$), fibrosis (cases: 11/27, 41%; controls: 10/35, 29%; $P=0.42$), mucosal hypertrophy
239 (cases: 3/27, 11%; controls: 5/35, 14%; $P=1.00$), glandular atrophy (cases: 2/27, 7%; controls: 3/35,
240 9%; $P=1.00$), the presence of spiral-shaped bacteria resembling *Helicobacter* species (cases: 3/27,
241 11%; controls: 9/35, 26%; $P=0.20$). Records of duodenal histology were available from 19/27 cats
242 in the case group and from 30/35 cats in the control group. In the duodenum, there was
243 lymphoplasmacytic infiltrate of the duodenal mucosa in 15/19 cases (79%) cases and 23/30
244 controls (77%; $P=0.69$). Gastric or duodenal neoplasia was also identified in 2/27 (7%) and 8/35
245 (23%; $P=0.16$) of cases and controls, respectively, with the histopathological diagnosis being
246 lymphoma in all cases (either gastric high-grade lymphoma localised in the fundic area or small-
247 cell duodenal lymphoma).

248 Overall, final diagnosis in the case group was inflammatory bowel disease (IBD) in 23/27 cases
249 (85%), neoplasia in 2/27 cases (7%), food hypersensitivity in one case (4%) and trichobezoar in
250 one case (4%). Final diagnosis in the control group was IBD in 21/35 cases (60%), acute gastritis
251 in two cases (5%), adenomatous polyps in one case (3%), diffuse adenomatous lesions in one case
252 (3%), lymphoma in 7 cases (20%), megaesophagus in one case (3%), ulcerative gastritis in one
253 case (3%), and trichobezoar in one case (3%).

254 **Therapy and outcome**

255 Most of the cats were treated medically with small doses of prednisolone (0.2-0.3 mg/kg/day)
256 and were exclusively fed one of two highly digestible wet foods (either Gastrointestinal Diet or
257 Hypoallergenic Diet, Royal Canin) over 3 to 5 meals. Balloon dilation was necessary in one
258 refractory case with inflammatory enteropathy, using a paediatric pyloric balloon (Olympus
259 Swift BP-2 Pyloric Balloon Dilator WA95093A 10x30mm, Olympus Winter & Ibe GmbH) inserted
260 in the pyloric lumen, and repeated several times. Another cat with IBD required pyloroplasty.
261 The clinical signs improved in all cats with medical therapy (and the balloon dilation for one cat),
262 with decreased frequency of vomiting. Cats with small-cell lymphoma were treated with a
263 combination of prednisolone (tapering protocol) and chlorambucil (15mg/m² four days every
264 three weeks; Lingard *et al.*, 2009). Finally, cats with high grade gastric lymphoma were offered
265 conventional chemotherapy but the owners elected palliative treatment with prednisolone.

266

267 **Estimated pyloric diameter**

268 The pyloric diameter was subjectively evaluated (by comparing with the size of the biopsy
269 forceps, as shown in Figure 3) in 18/27 cats in the case group, with a median size of 6.0 mm (range
270 3.0-8 mm). Given that the pylorus was easily intubated in control cats, the pylorus could not be
271 measured accurately, suggesting that the pyloric diameter was over 8.8 mm in all cases.

272 **[please insert figures 3(a) and 3(b)]**

273

274 **Discussion**

275 To our knowledge, this is the first study describing signalment, clinical, and specific endoscopic
276 findings in adult cats presumed to have acquired pyloric narrowing, suggested by the endoscopic
277 appearance and inability of an experienced endoscopist to intubate the pylorus with an 8.8 mm
278 external diameter flexible video gastroscope despite several attempts and despite the absence of
279 any mechanical obstruction. The entity described here is likely to reflect pathological
280 consequences of several underlying diseases, and the main objective was to describe the
281 associated clinicopathological findings. Endoscopy is known to be a safe tool for the investigation
282 of various gastrointestinal diseases in cats, and the results of the current study suggest that this
283 procedure is well suited to classifying disorders of the pylorus.

284

285 Despite being a sphincter with elasticity and contractility provided by the mucosal and muscular
286 layers, the pyloric opening has limited capacity to dilate (Biancani et al., 1980). To our knowledge,
287 neither acquired pyloric narrowing nor stenosis have ever previously been reported in adult cats,
288 perhaps, because a definitive diagnosis is not easy to establish given the lack of any standardised
289 approach for evaluating the internal diameter of the pylorus. Instead, cases can only ever be
290 'presumed' (rather than definitely confirmed) based upon the clinical signs (*eg*, vomiting of food,
291 variable delayed vomiting after eating) and the exclusion of other conditions responsible for
292 gastric delayed emptying (Washabau and Day, 2013).

293

294 One limitation of the current study is that the classification of cases and controls was made
295 subjectively, after inability to intubate the pylorus at endoscopy, since it is assumed that the
296 pylorus should be easily passable at endoscopy (Tams and Rawling, 2011; Washabau and Day,
297 2013). However, factors other than narrowing might have influenced success of intubation, such
298 as being a small-statured cat, over-insufflation (which leads to a reflex closure of the pylorus), the

299 use of prokinetic drugs (metoclopramide), operator experience, breed (*i.e.*, Siamese and Burmese
300 cats are suspected to have a narrower pyloric canal) and endoscopic diameter (Tams and
301 Rawling, 2011; Washabau and Day, 2013). Various steps were taken to minimise the influence of
302 these factors. For example, the same endoscopist performed all endoscopic procedures, and was
303 already experienced at the beginning of the study period, making variations in endoscopic skills
304 meaningless during the study. The same 8.8 mm external diameter flexible gastroscope was used
305 throughout, with care taken not to over-insufflate the stomach during the procedure. Other
306 causes of delayed gastric emptying (*e.g.* pyloric polyp, pyloric foreign body or pyloric mass) were
307 ruled out during the procedure although some cases did have neoplasia not affecting the pylorus.
308 Further, prokinetic drugs were not used and, in any case, the authors are not aware of any
309 pharmacological agents that has been shown to modify pyloric tone in cats (Smith et al., 2004).

310

311 Although domestic shorthair cats were the most common breed affected, Siamese cats were over-
312 represented; this is not surprising because pyloric stenosis has previously been reported in this
313 breed (Pearson et al., 1974; Syricle et al., 2013; Twaddle, 1971, 1970). Either this would confirm that
314 Siamese cats are predisposed to pyloric stenosis or, given the method of diagnosis, it might
315 instead suggest that Siamese cats simply have a narrower pyloric internal diameter. Thus, further
316 studies are needed comparing pyloric diameter in healthy Siamese cats and other breeds. Pyloric
317 narrowing was not associated with sex in the current study, which contrasts with two previous
318 case reports where most cases were female (Twaddle, 1971, 1970), but is similar to the findings
319 from another report where male and female cats were equally represented (Pearson et al., 1974).

320

321 Chronic vomiting was the most common clinical sign observed in both groups, although food
322 was more likely to be present in cases compared with controls. Thus, clinicians should be aware
323 that the presence of food in vomitus could be used the index of suspicion for pyloric narrowing.

324 Other clinical signs were only sporadically present, and the frequency did not differ between
325 cases and controls.

326

327 The ultrasonographic appearance of the pylorus was rarely abnormal in the cats of this study, in
328 contrast to canine pyloric gastropathy where thickening of the pylorus muscularis is observed
329 (Biller et al, 1994). Endoscopically, findings consistent with gastric inflammation (*e.g.*, oedema,
330 erythema, erosions, discolouration) were noted in many cats, whilst gastric ulceration and antral
331 polyps were rare. However, there were no significant differences between groups, suggesting
332 that these would not be useful discriminating signs for the diagnosis of presumed acquired
333 pyloric narrowing. Differential diagnosis of delayed gastric emptying or gastric obstruction was
334 supported by endoscopic procedure. Gastric retention was not commonly seen, possibly because
335 of the prolonged (>16 h) fast prior to the procedure itself and because of the lack of real
336 obstruction of the stomach. Therefore, , the degree of pyloric narrowing was less marked in our
337 cases compared with reported cases of congenital pyloric stenosis, therefore a complete gastric
338 obstruction was not expected.

339

340 As previously discussed, pyloric diameter was visually estimated, by comparing it with the width
341 between the jaws of the biopsy forceps when fully open; this suggests that, subjectively, pyloric
342 diameter of the cases was narrower than of the control cats, and might explain why the pylorus
343 could not be intubated. Pyloric antrum diameter was similarly endoscopically estimated in a case
344 of congenital pyloric stenosis (Syrle et al., 2013). In a recent prospective study in healthy cats,
345 median pyloric diameter was 9 mm (interquartile range 9-10 mm), consistent with our suspicion
346 of abnormal pyloric narrowing when it cannot be catheterised with an 8.8mm gastroscope
347 (Lamoureux et al., 2019). However, given that no guidelines were currently available for
348 measurement of the feline pyloric diameter in cats, further studies are needed.

349

350 The most common histological finding in cases was lymphoplasmacytic infiltration of the gastric
351 mucosa. Whilst these findings could suggest that an inflammatory process might be responsible
352 for a lack of elasticity leading to pyloric narrowing, the significance is not clear, given that a
353 similar proportion of controls had the same inflammatory findings. In dogs, enlarged folds
354 surrounding the pylorus are a common finding of pyloric hypertrophic gastropathy during
355 endoscopic procedure (Leib et al., 1993). This was not recorded in the cats of the current study,
356 despite a thickened mucosal fold which was observed for some cases. Moreover, in dogs, a
357 hypertrophy of the smooth muscular layer surrounding is another common histological finding,
358 which was not reported in the current study. However, histological features in our study were
359 based upon endoscopic biopsies of a small number of cases and muscular layers could therefore
360 not be assessed; full-thickness surgical biopsies or necropsy data would have been required to
361 assess more precisely the modifications of the muscular layers. In the absence of such biopsies,
362 muscular layer hypertrophy could only be considered unlikely based on the combination of
363 endoscopic and ultrasonographic appearance that were not suggestive for it. Based on this
364 hypothesis, this might suggest the aetiology of the apparent pyloric narrowing in cats is different
365 from that seen in dogs. Instead of muscular hypertrophy, mucosal fibrosis in a chronic
366 inflammatory context could explain a reduction in pyloric diameter along with loss of its
367 elasticity. Semi-quantitative evaluation of pyloric mucosal fibrosis, using Masson's Trichrome
368 staining for instance, would be an interesting approach to test this hypothesis. Indeed, mucosal
369 inflammation and secondary fibrosis were also suspected to be involved in acquired
370 inflammatory rectal strictures in a recent study (Lamoureux *et al.*, 2019), where chronic mucosal
371 changes finally impair sphincter elasticity and opening capacity. Further studies should now be
372 conducted to confirm these findings and explore aetiology in more detail.

373

374 Besides the limitations described above, others should be considered. First, the study was
375 retrospective in nature and we lacked specific tools to enable objective measurement of pyloric
376 diameter. Second, collection of gastric biopsies was not standardised amongst cases, in terms of
377 number of biopsies and sites sampled even if multiple biopsies were systematically performed,
378 which might have affected histopathological interpretation. Third, case numbers were relatively
379 small and some clinical details were incomplete. For example, some laboratory data were not
380 available, if performed by the practitioner prior to referral, and duodenal biopsies were not
381 available in each case. This might have led to underestimation of metabolic diseases and
382 duodenal diseases. Finally, given the lymphoplasmacytic inflammation commonly identified,
383 prednisolone was often trialled at anti-inflammatory doses. However, follow-up was not
384 available in all cases meaning that response to this therapy cannot be determined precisely. Given
385 these listed limitations, it is suggested that prospective studies-including an appropriate pyloric
386 measuring tool-should be considered to examine cases of presumed acquired pyloric narrowing
387 more completely. Prospective studies would enable the outcome of such cases to be elucidated,
388 as well as the response to therapy determined.

389

390 **Conclusion**

391 In summary, in this preliminary study, we have described a series of 27 cases with presumed
392 acquired pyloric narrowing. Compared with 35 cats without this condition, the vomitus of these
393 cats was more likely to contain food, and Siamese cats were over-represented. One possible
394 explanation for acquired pyloric narrowing could be peri-pyloric cicatricial fibrosis secondary to
395 an inflammatory process. However, further studies are needed to better describe and understand
396 this syndrome.

397

398 **Acknowledgments**

399 The authors greatly thank all the clinicians and the diagnostic imaging service for their
400 implication in this study.

401

402 **Author's note**

403 These results were presented as an oral communication at the ECVIM-CA congress in
404 September 2016.

405

406 **Conflict of interest declaration**

407 AJG's academic post at the University of Liverpool is financially supported by Royal Canin.

408 FD's clinical position at CHUVA-Ecole Nationale Vétérinaire d'Alfort was financially supported
409 by Royal Canin.

410

411 **Funding**

412 The authors received no financial support for the research, authorship, and/or publication of
413 this article.

414

415 **Ethical approval and informed consent statement**

416 This retrospective study involved the use of client-owned animal only, and followed
417 internationally recognized high standards of individual veterinary clinical patient care. Ethical
418 Approval from a committee was not therefore needed. The owners gave written informed
419 consent for all the procedures.

420

421 **References**

- 422 Biancani, P., Zabinski, M.P., Kerstein, M.D., et al. (1980) **Mechanical characteristics of the cat**
423 **pylorus.** *Gastroenterology* 78:301-309.
- 424 Couturier, L., Rault, D., Gatel, L., et al. (2012) **Ultrasonographic characterization of the feline**
425 **cardia and pylorus in 34 healthy cats and three abnormal cats.** *Veterinary Radiology &*
426 *Ultrasound* 53, 342-347.
- 427 Lamoureux, A., Benchekroun, G., German, A. J., et al. (2019) **An endoscopic method for semi-**
428 **quantitatively measuring internal pyloric diameter in healthy cats: A prospective study of 24**
429 **cases.** *Research in Veterinary Science* 122, 165-169.
- 430 Leib, M. S., Saunders, G. K., Moon, M. L., et al. (1993) **Endoscopic Diagnosis of Chronic**
431 **Hypertrophic Pyloric Gastropathy in Dogs.** *Journal of Veterinary Internal Medicine* 7, 335-
432 341.
- 433 Lingard, A. E., Briscoe, K., Beatty, J. A., et al. (2009) **Low-grade alimentary lymphoma:**
434 **clinicopathological findings and response to treatment in 17 cases.** *Journal of Feline Medicine*
435 *and Surgery* 11, 692-700.
- 436 Martin-Flores, M., Scrivani, P. V., Loew, E., et al. (2014) **Maximal and submaximal mouth**
437 **opening with mouth gags in cats: Implications for maxillary artery blood flow.** *The Veterinary*
438 *Journal* 1, 60-64.
- 439 Pearson, H., Gaskell, C. J., Gibbs, C., et al. (1974) **Pyloric and oesophageal dysfunction in the**
440 **cat.** *Journal of Small Animal Practice* 15, 487-502.
- 441 Smith, A. A., Posner, L. P., Goldstein, R. E., et al. (2004) **Evaluation of the effects of**
442 **premedication on gastroduodenoscopy in cats.** *Journal of the American Veterinary Medical*
443 *Association* 225, 540-544.

444 Syrcle, J. A., Gambino, J. M., Kimberlin, W. W. (2013) **Treatment of pyloric stenosis in a cat via**
445 **pylorectomy and gastroduodenostomy (Billroth I procedure).** *Journal of the American Veterinary*
446 *Medical Association* 242, 792-797.

447 Tams, T. R., Rawlings, C. A. (2011) *Small Animal Endoscopy*. 3rd ed. Saint Louis : Elsevier,
448 2011.

449 Twaddle, A. A. (1970) **Pyloric stenosis in three cats and its correction by pyloroplasty.** *New*
450 *Zealand Veterinary Journal* 18, 15-17.

451 Twaddle, A. A. (1971) **Congenital pyloric stenosis in two kittens corrected by pyloroplasty.**
452 *New Zealand Veterinary Journal* 19, 26-27.

453 Washabau, R. J., Day, M. J. (2013) *Canine and feline gastroenterology*. Saint Louis: Elsevier
454 Saunders, pp 606-650.

455 Washabau, R. J., Day, M. J., Willard, M. D., *et al.* (2010) **Endoscopic, biopsy, and**
456 **histopathologic guidelines for the evaluation of gastrointestinal inflammation in companion**
457 **animals.** *Journal of Veterinary Internal Medicine* 24, 10-26.

458 Willard, M. D., Mansell, J., Fosgate, G. T., *et al.* (2008) **Effect of Sample Quality on the**
459 **Sensitivity of Endoscopic Biopsy for Detecting Gastric and Duodenal Lesions in Dogs and**
460 **Cats.** *Journal of Veterinary Internal Medicine* 22, 1084-1089.

461
462
463

464 **Figure legends**

465 **Figure 1.** Ultrasonographic appearance of a normal feline pylorus (a) and the similar
466 appearance of the pylorus in a cat identified with pyloric narrowing (b), showing the absence of
467 muscularis layer hypertrophy or loss of layering at the pyloric level.

468

469 **Figure 2.** Illustrations of narrowed pylorus. (a): narrowed pylorus with surrounding mucosal
470 oedema. (b): narrowed pylorus with surrounding mucosal erosions and erythema. (c):
471 narrowed pylorus with surrounding additional mucosal fold.

472

473 **Figure 3.** Endoscopic appearance of a narrowed pylorus: the diameter is compared to the
474 closed (a) and opened (b) biopsy forceps

475

Table 1. Signalment and clinical findings in cats with pyloric narrowing (cases) and cats with gastrointestinal signs without pyloric narrowing (controls)

	Cases	Controls	P-value
Age (years)	8 (2.0-14.5)	9 (0.7-18)	0.473
Type of food			0.199
Dry food	12/17 (70%)	9/24 (38%)	
Wet food	2/17 (12%)	5/24 (20%)	
Mix	3/17 (18%)	9/24 (38%)	
Home-made	0/17 (0%)	1/24 (4%)	
Breed			0.037 ¹
Domestic Shorthair	18/27 (66%)	26/35 (74%)	
Birman	1/27 (4%)	4/35 (11%)	
Siamese	6/27 (22%)	1/35(3%)	
Maine Coon	0/27 (0%)	1/35 (3%)	
Angora	0/27 (0%)	1/35 (3%)	
British Shorthair	0/27 (0%)	1/35 (3%)	
Persian	0/27 (0%)	1/35 (3%)	
Abyssinian	1/27 (4%)	0/35 (0%)	
Rex Devon	1/27 (4%)	0/35 (0%)	
Weight (kg)	4.0 (2.3-6.0)	4.5 (2.4-7.1)	0.253
Sex			0.22
Female	15/27 (55%)	14/35 (40%)	
Male	12/27 (45%)	21/35 (60%)	
Neuter status	26/27 (96%)	34/35 (97%)	1.000 fi
Duration of signs (m)	4 (0.1-42)	5.5 (0.1-60)	0.496
Chronic (>3 weeks)	18/22 (82%)	28/34 (82%)	1.000
Content of vomiting			0.005
Food	23/25 (92%)	17/30 (57%)	
Liquid	2/25 (8%)	13/30 (43%)	
Frequency of vomiting			<0.001
No vomiting	0/21 (0%)	3/28 (11%)	
1-3/month	0/21 (0%)	8/28 (29%)	
1-3/ week	9/21 (43%)	13/28 (46%)	
Daily	12/21 (57%)	4/28 (14%)	
Time of vomiting after meal			0.487
No clear pattern	4/16 (25%)	5/17 (29%)	
Always within 30 min	7/16 (44%)	4/17 (24%)	
Between 30 min and 4h	2/16 (12%)	2/17 (12%)	
Always longer than 4h	3/16 (19%)	6/17 (35%)	
Dysorexia	4/27 (15%)	11/35 (31%)	0.149

Diarrhoea	6/27 (22%)	10/35 (29%)	0.232
Weight loss	10/27 (37%)	16/35 (46%)	0.606

478 Results are expressed as proportions with corresponding percentages in brackets. Reported P-
479 values are those from either χ^2 tests, or Fisher's exact tests when sample size was small (*e.g.*,
480 when the expected values in any cell within a contingency table was <5). ¹ P-value corresponds
481 to comparison between the proportion of Siamese cats between groups

482

483 **Table 2. Biochemical findings in cats with pyloric narrowing (cases) and cats with**
 484 **gastrointestinal signs without pyloric narrowing (controls)**

485

	Case group	Control group	P-value
486 Urea (mmol/L)	8.49 [5.16-36.6] N=23	8.4 [5.99-14.8] N=26	0.756
487 Creatinine (μmol/L)	124 [8-25] N=23	14.3 [70.7-194] N=27	0.969
488 Total Protein (g/L)	70 [53-90] N=21	70.1 [54-88] N=21	0.734
489 Albumin (g/L)	29.5 [24-35] N=20	29 [24-40] N=19	0.297
490 ALP (UI/L)	55 [20-119] N=22	58.5 [14-214] N=24	0.538
491 ALT (UI/L)	52.5 [9-162] N=22	45 [27-248] N=25	0.856
492 Glucose (mmol/L)	7.05 [5.1-12.5] N=22	6.61 [2.94-14.4] N=23	0.162
493 fPLi (μg/L)	135 [1.1-2.9] N=6	2.1 [0.6-8.5] N=11	0.417
494 Total thyroxine (nmol/L)	28.4 [16-37] N=11	32 [12-49.8] N=17	0.588

496 Results are reported as median [range] and number of cats. Reported *P*-values are those from
 497 the Mann-Whitney U-test. ALP: alkaline phosphatase; alanine aminotransferase; fPLi: feline
 498 pancreatic lipase.

499

500
501

Table 3. Hematological findings in cats with pyloric narrowing (cases) and cats with gastrointestinal signs without pyloric narrowing (controls)

	Case group	Control group	P-value
Haematocrit (L/L)	0.360 [0.206-0.455] n=15	0.352 [0.218-0.460] n=20	0.701
Haemoglobin (g/L)	126 [74-143] n=14	117 [88-143] n=18	0.676
Leucocyte count (10⁹/L)	10.3 [4.48-15.4] n=14	9.12 [4.79-33.3] n=18	0.587
Neutrophils (10⁹/L)	6.69 [2.03-11.9] n=14	6.01 [1.19-25.9] n=17	0.921
Eosinophils (10⁹/L)	0.520 [0.150-1.42] n=14	0.495 [0.160-3.26] n=18	0.790
Monocytes (10⁹/L)	0.300 [0.100-1.114] n=14	0.555 [0.060-4.97] n=18	0.057
Lymphocytes (10⁹/L)	2.12 [0.570-3.34] n=14	1.87 [0.420-4.54] n=17	0.921
Platelets (10⁹/L)	249.5 [52-383] n=14	294 [29-885] n=18	0.342

502 Results are expressed as median [range], whilst reported *P*-values are those from the Mann-
503 Whitney U-test.

504

505 **Table 4. Ultrasonographic findings in in cats with pyloric narrowing (cases) and cats with**
 506 **gastrointestinal signs without pyloric narrowing (controls)**
 507

Ultrasonographic findings	Cases	Controls	P-value
Digestive tract			
Abnormal gastric content	4/27 (15%)	4/35 (11%)	0.719
Pyloric thickening	2/27 (7%)	4/35 (8%)	0.689
Thickening of other regions	8/27 (30%)	13/35 (37%)	0.596
<i>Stomach other than pylorus</i>	1	3	
<i>Duodenum</i>	0	4	
<i>Jejunum</i>	5	4	
<i>Ileum</i>	2	1	
<i>Colon</i>	0	1	
Other abdominal organs			
Pancreas (<i>hyperechogenicity or nodular appearance</i>)	1/27 (4%)	5/35 (14%)	0.220
Liver	7/27 (26%)	10/35 (29%)	1.000
<i>Hepatomegaly</i>	1	4	
<i>Hyperechogenicity</i>	5	3	
<i>Biliary sludge</i>	1	3	
Kidneys	4/27 (15%)	7/35 (20%)	0.742
<i>Signs of chronic nephropathy</i>	4	6	
<i>Nephromegaly</i>	0	1	
Spleen	2/27 (8%)	2/35 (6%)	1.000
<i>Mild splenomegaly</i>	0	1	
<i>Nodule</i>	1	0	
<i>Mild heterogenicity</i>	1	1	
Lymph node (LN) enlargement	8/27 (30%)	10/35 (29%)	1.000
<i>Gastric</i>	0	0	
<i>Hepatic</i>	1	2	
<i>Jejunal</i>	1	4	
<i>Ileo-colic</i>	3	2	
<i>Colic</i>	2	0	
<i>>2 different LNs</i>	1	2	

508 Results are expressed as proportions with corresponding percentages in brackets. Reported P-
 509 values are those from either χ^2 tests, or Fisher's exact tests when sample size was small (e.g.,
 510 when the expected values in any cell within a contingency table was <5).

511
512

Table 5. Endoscopic findings of the stomach in in cats with pyloric narrowing (cases; 27) and cats with gastrointestinal signs without pyloric narrowing (controls; 35)

	Cases				Controls				P-value ¹
	0	1	2	3	0	1	2	3	
Hyperaemia	9 (33%)	16 (59%)	2 (7%)	0 (0%)	7 (20%)	17 (49%)	11 (31%)	0 (0%)	0.062
Oedema	10 (37%)	11 (41%)	4 (15%)	2 (7%)	10 (29%)	14 (40%)	9 (26%)	2 (5%)	0.736
Discolouration	12 (44%)	12 (44%)	3 (12%)	0 (0%)	9 (26%)	21 (60%)	5 (14%)	0 (0%)	0.303
Erosions/ ulcers	22 (82%)	2 (7%)	3 (11%)	0 (0%)	27 (77%)	2 (6%)	5 (14%)	1 (3%)	0.803
Content	27 (100%)	0 (0%)	0 (0%)	0 (0%)	34 (97%)	1 (3%)	0 (0%)	0 (0%)	1.000
Pylorus intubation	0 (0%)	0 (0%)	2 (7%)	25 (93%)	33 (94%)	2 (6%)	0 (0%)	0 (0%)	(discrimination criterion)
Mass/polyp		1 (4%)				4 (11%)			0.376
Foreign body		1 (4%)				1 (3%)			1.000

513 *Endoscopic findings graded according to the WSAVA guidelines. Code: Normal=0; Mild=1; Moderate=2; Severe=3.*

514 ¹*Variables tested either with a Fischer's test (mass/polyp and foreign body) or Cochran-Armitage trend test (all other*

515 *variables).*

516

517
518

Table 6. Histological findings in gastro-duodenal biopsies of cats with pyloric narrowing (cases; 27) and cats with gastrointestinal signs without pyloric narrowing (controls; 35)

Histological findings	Cases				Controls				P-value ¹
	0	1	2	3	0	1	2	3	
Stomach									
Lymphocytic-plasmacytic infiltrate	9 (33%)	12 (44%)	5 (19%)	1 (4%)	14 (40%)	13 (37%)	5 (14%)	3 (9%)	0.959
Eosinophilic infiltrate	25 (93%)	2 (7%)	0 (0%)	0 (0%)	34 (97%)	1 (3%)	0 (0%)	0 (0%)	0.575
Mucosal hypertrophy	24 (89%)	3 (11%)	0 (0%)	0 (0%)	30 (86%)	5 (14%)	0 (0%)	0 (0%)	1.000
Fundic gland atrophy	25 (93%)	2 (7%)	0 (0%)	0 (0%)	32 (91%)	3 (9%)	0 (0%)	0 (0%)	1.000
Fibrosis	16 (59%)	11 (41%)	0 (0%)	0 (0%)	25 (71%)	10 (29%)	0 (0%)	0 (0%)	0.418
<i>Helicobacter</i>	24 (89%)	3 (11%)	0 (0%)	0 (0%)	26 (74%)	9 (26%)	0 (0%)	0 (0%)	0.202
Duodenum									
Lymphocytic-plasmacytic infiltrate	4 (21%)	10 (52%)	3 (16%)	2 (11%)	7 (23%)	12 (40%)	7 (23%)	4 (14%)	0.690
Gastric or duodenal neoplasia									
		2 (7%)				8 (23%)			0.164
<i>Gastric high grade lymphoma (fundus)</i>		1				4			
<i>Duodenal small-cell lymphoma</i>		1				3			
<i>Polyp</i>		0				1 (antrum)			

519 Lesions were graded according to the WSAVA guidelines. Code: Normal=0; Mild=1; Moderate=2; Severe=3. ¹Variables
520 tested either with a Fisher's test (neoplasia) or Cochran-Armitage trend test (all other variables).

521

